Home › Funds › MPM BioImpact LLC › NGNE
MPM BioImpact LLC position in NGNE
NEUROGENE INC · Health Care
MPM BioImpact LLC reported holding 771,839 shares of NGNE (NEUROGENE INC) in its Q3 2026 13F filing — a position valued at US$21.5M, representing 1.65% of its reported portfolio and ranking #29 among its reported holdings. MPM BioImpact LLC first reported this position in Q3 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's NGNE position evolved
MPM BioImpact LLC first disclosed a stake in NGNE in Q3 2026 at 771,839 shares (US$21.5M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 771.84K | $21.47M | New |
About NGNE and 13F data
NGNE (NEUROGENE INC) is a Health Care company. 41 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$51.9M), Casdin Capital (US$44.1M), Redmile Group, LLC (US$43.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NGNE
- Samsara BioCapital, LLC 1.87M sh · $51.94M · Q3 2026
- Casdin Capital 1.59M sh · $44.10M · Q3 2026
- Redmile Group, LLC 1.56M sh · $43.46M · Q3 2026
- RTW INVESTMENTS, LP 1.51M sh · $42.08M · Q3 2026
- EcoR1 Capital, LLC 1.27M sh · $35.37M · Q3 2026
- BAKER BROS. ADVISORS LP 991.69K sh · $27.59M · Q3 2026
- Trails Edge Capital Partners, LP 964.88K sh · $26.84M · Q3 2026
- Tyro Capital Management LLC 304.40K sh · $8.47M · Q3 2026
- GREAT POINT PARTNERS LLC 300.00K sh · $8.35M · Q3 2026
- Jones Hill Capital LP 217.70K sh · $6.06M · Q3 2026
- DAFNA Capital Management LLC 150.53K sh · $4.19M · Q3 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held NGNE?
MPM BioImpact LLC has disclosed NGNE holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is MPM BioImpact LLC's current position in NGNE?
As of Q3 2026, MPM BioImpact LLC holds 771.84K shares of NGNE (NEUROGENE INC), valued at $21.47M, representing 1.65% of its reported portfolio and ranking #29.
Has MPM BioImpact LLC been buying or selling NGNE?
In the latest 13F filing (Q3 2026), MPM BioImpact LLC newly opened its position in NGNE.
Which other funds hold NGNE?
Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, Redmile Group, LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.